

Annual Review of Pharmacology and Toxicology

Addressing Ancestry and Sex Bias in Pharmacogenomics

Manuel Corpas,^{1,2} Moneeza K. Siddiqui,³
Opeyemi Soremekun,⁴ Rohini Mathur,⁵
Pender Gill,⁶ and Segun Fatumo^{4,7}

¹School of Life Sciences, University of Westminster, London, United Kingdom

²Cambridge Precision Medicine Limited, ideaSpace, University of Cambridge Biomedical Innovation Hub, Cambridge, United Kingdom

³Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom

⁴African Computational Genomics (TACG) Research Group, Medical Research Council/ Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda

⁵Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom

⁶Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom

⁷Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom; email: segun.fatumo@lshtm.ac.uk

ANNUAL
REVIEWS **CONNECT**

www.annualreviews.org

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

Annu. Rev. Pharmacol. Toxicol. 2024. 64:53–64

First published as a Review in Advance on
July 14, 2023

The *Annual Review of Pharmacology and Toxicology* is
online at pharmtox.annualreviews.org

<https://doi.org/10.1146/annurev-pharmtox-030823-111731>

Copyright © 2024 by the author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information.



Keywords

pharmacogenomics, underrepresented populations, alleles, haplotypes, biogeographical regions, diversity genomics

Abstract

The association of an individual's genetic makeup with their response to drugs is referred to as pharmacogenomics. By understanding the relationship between genetic variants and drug efficacy or toxicity, we are able to optimize pharmacological therapy according to an individual's genotype. Pharmacogenomics research has historically suffered from bias and underrepresentation of people from certain ancestry groups and of the female sex. These biases can arise from factors such as drugs and indications studied, selection of study participants, and methods used to collect and analyze data. To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcase

CYP2D6, a gene that metabolizes approximately 25% of all prescribed drugs. We also show how the historical underrepresentation of females in clinical trials has led to significantly more adverse drug reactions in females than in males.

INTRODUCTION

Our understanding of how genetic variants influence drug response has been revolutionized since the release of the Human Genome Project (1). Understanding the genetic composition of individuals has improved our ability to identify beneficial effects of pharmacological treatments as well as harms related to drug addiction, drug dependence or resistance, and adverse drug reactions (ADRs) across entire populations. Predictions of drug reactions and their expected effect have produced important benefits for well-characterized drugs such as those metabolized by cytochrome P450 genes (e.g., *CYP2D6*) (2–4) and anticoagulant drugs such as warfarin (5–7), among many others (8–10).

Despite these incontrovertible advances, our ability to translate pharmacogenomic knowledge into clinical benefit remains inequitable for certain population groups, due to a lack of data sets representing their genetic variation. In terms of sex, females have historically been underrepresented in clinical trials (11–13), meaning that if a drug is tested primarily on males, its effectiveness and safety in females may not be fully understood. This lack of representation for certain groups is a systemic problem affecting not only pharmacogenomics but also genome medicine as a whole, as illustrated by some seminal studies (14, 15).

The first systematic investigation into population biogeographical diversity for genetic studies was published in 2009 (14) and revealed that 96% of participants of all genome-wide association studies (GWASs) existing at that time were of European descent. A similar analysis was replicated in 2016 by Popejoy & Fullerton (16), showing that the representation of non-European participant data from across the globe for GWASs was far from equitable. While Europeans represent only 16% of the global population today, around 78% of data used in GWASs originate from people of European descent. Recent studies have shown that in spite of several calls for more diversity in genomics studies, the gap continues to widen (17–20).

Significant disparities in the biogeographical representation of genomic data sources have increasingly triggered international efforts to ensure the benefits of genomic science reach all populations, regardless of ancestry or sex. Greater representation of diverse populations not only is of interest for the underrepresented individuals themselves but also is paramount for uncovering true causal associations between genotype and phenotype, which currently may be confounded by effects such as linkage disequilibrium, where DNA markers occur together more often than can be accounted for by chance because of their physical proximity on a chromosome. The equitable representation of individuals in genomic studies is therefore a question not only of moral imperative but of scientific progress.

Although the lack of data from underrepresented populations has been assessed for GWASs, the extent to which this bias also affects pharmacogenomic data sources remains unknown. There is evidence of dosage algorithms being less accurate for underrepresented populations (21, 22), reflecting participant selection biases in public reference databases. Concurring with previous studies on genetic diversity, we hypothesize that the number of individuals in pharmacogenomic study resources is a proxy for the performance of dosage algorithms in that particular population subgroup.

QUANTIFYING BIOGEOGRAPHICAL BIAS IN PUBLIC DATA SOURCES

In order to establish the degree of bias in publicly available data sources, we downloaded the full contents of PharmGKB (23, 24).¹ PharmGKB is a leading resource that aggregates, curates, and integrates data on pharmacogenomics. PharmGKB constitutes a catalog of genetic variants affecting drug responses. Using PharmGKB as a reference, we are able to relate the number of individuals (cases) from different biogeographical regions associated with drug response annotations. The biogeographical groups reported in PharmGKB are based on a standardized system for annotating populations in pharmacogenetic research (25).

As of December 2022, PharmGKB had 11,198 variant drug annotations. When analyzing the biogeographical groups in the studies from which drug annotations were derived, heterogeneity was found. In total, we counted 509 different biogeographical groups, the vast majority of which consisted of combinations of multiple ancestry groups, which were difficult to categorize. The number of individuals in unclassified groups amounted to a total of 2,509,439 (49.78% of the total number of cases reported for all collected studies within PharmGKB). Heterogeneous groups, where discrete biogeographical groups could not be assessed, were discarded. We cannot rule out that this heterogeneity in annotation of biogeographical groups could lead to a selection bias, which therefore should be acknowledged as a potential limitation. The way in which study data are reported by PharmGKB also does not allow us to identify the origin of the studies from which these data are generated. Therefore, the description of biogeographical groups is limited to the number of cases described for each study according to PharmGKB's annotation. The biogeographical groups for which we could assign unequivocal study cases amounted to 2,531,125 individuals (50.22% of all individuals in the collated PharmGKB studies; **Figure 1**). These individuals were assigned to the following biogeographical groups: European, East Asian, Central/South Asian, African American or Afro-Caribbean, Latino, sub-Saharan African, Near Eastern, or American. We found that 63.56% (1,608,723) of these individuals were of European origin, and 28.05% were East Asian (710,073). From the rest, 3.66% were African (sub-Saharan, African American, Afro-Caribbean), 1.55% were Latinos, and 0.1% were indigenous Americans. These proportions appear to be consistent with the findings reported by Popejoy & Fullerton (16), who calculated 3%, 0.54%, and 0.05% of GWAS subjects as being of African, Latino, and indigenous/native descent, respectively. The tendency of an increased representation of East Asians is mirrored in our results, doubling from the 14% observed by Popejoy & Fullerton to 28% in our data set. Similarly, other underrepresented populations had no greater presence than in GWASs. Another limitation of this analysis is that it does not account for the resampling of data sets across independent studies, and it is likely that the cohorts used in publicly available pharmacogenomics studies have been used multiple times. This effect of double counting with current data sets is impossible to estimate, as individual genotype data are anonymized.

The total number of studies (calculated as distinct PubMed IDs) that have been reported so far in PharmGKB amounts to 3,682, involving 1,085 genes and 889 drugs or combinations thereof. In order to assess the implications of pharmacogenomic biases due to the lack of biogeographical representation, we focus our attention on *CYP2D6* and also include warfarin as an example of the issues.

GENOMIC DIVERSITY OF *CYP2D6*

CYP2D6 is a highly polymorphic gene commonly involved in ADRs. The resulting encoded enzyme performs differently depending on the type of variants that it harbors, significantly affecting

¹The data source and the code developed to analyze the data are available under a Massachusetts Institute of Technology license and can be accessed here: <https://github.com/manuelcorpas/13-PGX-REPO>.




Figure 1

Breakdown of biogeographical groups from PharmGKB studies whose source cohorts have been classified. We found that 63.56% (1,608,723) of these individuals were of European origin, and 28.05% were East Asian (710,073). From the rest, 3.66% were African (sub-Saharan, African American, Afro-Caribbean), 1.55% were Latinos, 0.93% were Near Eastern, and 0.1% were indigenous Americans.

its ability to metabolize prescribed drugs. *CYP2D6* is a very important gene for pharmacogenomics, metabolizing up to 25% of currently prescribed drugs (26), which include antipsychotic drugs, antiarrhythmic agents, tricyclic antidepressants, β -adrenergic receptor antagonists, opioids, and the estrogen receptor antagonist tamoxifen.

The pharmacogenomic effects of *CYP2D6* result in a lack of therapeutic effect or an ADR due to fast metabolism of precursors into the active form. For instance, codeine, a drug metabolized by *CYP2D6*, is regularly prescribed to manage pain crises from sickle cell disease (27), a disease that is overrepresented among Africans. When administered to the patient, codeine converts differently depending on metabolizer status, which is determined by variations in *CYP2D6*. This process leads to significant health impacts as a result. **Table 1** (adapted from 28) shows the different effects that metabolizer status may confer to a patient administered with codeine.

In order to predict codeine drug reactions, it is first necessary to identify the individual's haplotype (group of alleles that tend to occur together). A haplotype is inherited from each parent, and in order to distinguish one combination of variants from another, the numbering system of

Table 1 Different impacts of the metabolizer status of an individual for the drug codeine

Metabolizer status	Amount of codeine converted to morphine	Impact on the patient/recommendations	Frequency (reference)
Poor	Low (10%)	Insufficient pain relief, change medication	5–10% of European patients, although it is believed that this is reduced in African patients
Intermediate	Reduced	Use label-recommended dose; if not effective, change medication	2–11% of European patients 20–28% of African patients (29)
Extensive	Normal	Use label-recommended dosing	77–92% of European patients ~50% of African patients (30)
Ultrarapid	High (40–51%)	Potential for morphine toxicity, which can translate into fatal concentrations in breast milk; change medication	28% of North Africans, Ethiopians, and Arabs 10% of Caucasians, 3% of African Americans (31)

Table adapted from Reference 28.

star alleles is used. An expression of a haplotype in a gene may be called *2 (normal function). Another combination may be called *3 (no function). Whenever genetic testing is performed, the results are noted as two numbers, each one representing a combination of variants in that gene. This haplotype representation is denoted as the two-star allele separated by a slash in the middle (e.g., *2/*3; intermediate metabolizer). Depending on the haplotype a person has, a different metabolizer status can be inferred. Haplotype frequencies vary significantly among different biogeographical groups. **Table 2** shows a biogeographical breakdown of the differing frequency of haplotypes by biogeographical group for the *CYP2D6* gene (30).

In a study by Twesigomwe et al. (33), it was found that for 961 individuals of sub-Saharan African ancestry studied with high-depth whole-genome analysis, more than 5% carried novel (unidentified to date) alleles within this gene. This study also emphasized the need for not just considering one single African population as a general proxy for another when developing pharmacogenomic therapeutics. Greater diversity in *CYP2D6* has been demonstrated in Africa versus Europe or Asia, and alleles that are uniquely African have been identified that can alter drug metabolizer status (34).

We have shown how *CYP2D6* haplotype frequencies vary according to population ancestries, with different ancestries displaying more diverse haplotypes, conditioning the optimal dosage level for drug administration. Understudied populations with more diverse haplotype frequencies are therefore more likely to be affected by imprecision when applying pharmacogenomic annotations to dosage administration. Therefore, pharmacogenomics can differ across different ancestral groups, with significant impact on drug efficacy and safety (35–37). However, unequal representation of biogeographical regions is not the only urgent bias to address.

GENOMIC DIVERSITY OF WARFARIN

Warfarin has remained the most commonly prescribed vitamin K oral anticoagulant worldwide since its approval in 1954 (38). Warfarin is prescribed to prevent blood clots, stroke, and heart attacks with genetic variations in *CYP2C9* and *VKORC1* encoding for the enzymes that metabolize and activate it (38). Such variations can affect drug response, leading to variations in drug efficacy and safety, with genetic ancestry playing a determinant role in the diversity of warfarin pharmacology. For example, individuals of African descent may have a higher prevalence of *CYP2C9* and *VKORC1* genetic variants associated with increased warfarin sensitivity (39). In particular, African Americans have been found to be more likely to carry variants of these genes

Table 2 Allele frequencies of the first 20 CYP2D6 haplotypes broken down by biogeographical group

CYP2D6 allele	African allele frequency	African American allele frequency	European allele frequency	Middle Eastern allele frequency	East Asian allele frequency	South/Central Asian allele frequency	Americas allele frequency	Oceanian allele frequency
*1	32.377	33.631	37.123	40.724	35.585	48.930	50.518	73.000
*2	19.671	15.608	26.833	21.718	12.664	28.845	22.732	1.200
*3	0.031	0.278	1.364	0.083	0.001	0.025	0.603	0.180
*4	3.344	6.387	18.174	7.800	0.648	7.873	10.764	2.480
*5	6.241	6.375	2.829	2.336	5.170	3.286	2.107	4.320
*6	<0.001	0.216	0.960	0.576	0.015	<0.001	0.335	<0.001
*7	<0.001	<0.001	0.094	<0.001	0.001	ND	<0.001	<0.001
*8	<0.001	<0.001	0.022	<0.001	<0.001	ND	0.055	<0.001
*9	0.080	0.428	1.997	<0.001	0.167	0.757	1.113	<0.001
*10	6.615	4.067	2.780	3.490	42.430	17.357	2.566	2.500
*11	<0.001	<0.001	0.013	<0.001	<0.001	ND	<0.001	<0.001
*12	<0.001	0.080	0.008	<0.001	<0.001	ND	2.100	ND
*13	0.510	<0.001	0.187	ND	<0.001	ND	ND	0.400
*14	0.170	<0.001	<0.001	0.150	0.752	<0.001	0.293	<0.001
*15	<0.001	<0.001	0.005	ND	<0.001	ND	0.503	<0.001
*17	19.946	18.138	0.312	1.583	0.010	0.136	2.480	0.050
*18	<0.001	<0.001	<0.001	<0.001	0.074	ND	<0.001	ND
*19	<0.001	<0.001	0.013	<0.001	<0.001	ND	0.273	<0.001
*20	<0.001	<0.001	<0.001	<0.001	<0.001	ND	<0.001	<0.001

Abbreviation: ND, no data. Data from the Clinical Pharmacogenetics Implementation Consortium (30).

that result in decreased metabolism of warfarin and increased sensitivity to its effects, requiring higher doses to achieve therapeutic benefit (40). On the other hand, individuals of East Asian descent may have a higher prevalence of genetic variants associated with decreased warfarin sensitivity (41). It is also suggested that diverse populations such as African Americans, Latinos, and South Asians have different variability in warfarin dosage requirements and a higher risk for warfarin-related adverse events compared to Europeans (42).

The implications of these different dose requirements are therefore significant in clinical care, where overdosing can lead to serious bleeding events, while underdosing can result in inadequate anticoagulation and an increased risk of blood clots. Therefore, determining the appropriate dose of warfarin for an individual patient is crucial to ensure optimal treatment outcomes. Despite this influence on treatment outcomes, most of the studied dosing algorithms and phenotype-genotype relationships still continue to be most specific for Europeans or East Asians (43).

GENDER AND SEX IN PHARMACOGENOMIC STUDIES

Sex (the biological concept) and gender (the social construct) play significant roles in health and health behaviors. Studies have found differential drug efficacy and safety profiles for males and females, from cholesterol-lowering proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (44) to therapies for chronic pain management (45) and mental health (46). Moreover, changing hormonal levels in postmenopausal women can alter biological processes in the body, a fact not often considered in the design of studies examining drug efficacy or safety over a woman's life course.

Post hoc genomic analyses of drug efficacy and safety using randomized controlled trials have become increasingly popular. Pharmaceutical companies see the value in gathering genotypic data on trial participants to better understand the underlying genetic factors that may impact the efficacy and safety of new therapies. This approach has paid rich dividends as scientists in academia and industry are now able to collaborate in large-scale pharmacogenomic studies using high-quality randomized control trial (RCT) data, paving the way for precision medicine (47).

Unfortunately, the representation of women in RCTs is not always equitable and is often skewed in relation to their comparative risk of diseases. For example, in 192 clinical trials of individuals with chronic kidney disease, only 45% of trial participants were women, whereas women are 33% more likely than men to suffer from chronic kidney disease (48). This mismatch in participant-to-prevalence ratios is particularly steep for women of childbearing ages, who are often explicitly excluded from RCTs for safety reasons. Disentangling the roles of genetics, biology, and environmental effects in this subgroup of women is therefore more challenging, and researchers must then rely on the availability of observational data resources to conduct postauthorization safety studies.

An example in pharmacogenomics where biological sex appears to modify the association of genetic factors with drug efficacy is the PCSK9-R46L variant. PCSK9 is a potent natural regulator of plasma low-density lipoprotein cholesterol (LDL-C) levels. Levels of PCSK9 have been found to be higher in premenopausal women than they are in men and postmenopausal women (49, 50). Pharmacological inhibition of PCSK9 has shown efficacy in reducing LDL-C levels and therefore the risk of major adverse coronary outcomes (51). However, recent trials and large observational studies have shown that inhibition using the agent evolocumab achieves stronger inhibition in men compared to women (45, 52). In certain trials of drug efficacy, fewer women were able to achieve target LDL-C levels as compared to men. A meta-analysis of real-world data settings confirms this finding, with only 25% of women achieving target reductions in LDL-C levels compared to 50% of men (53).

GENDER BIAS IN ADVERSE DRUG REACTIONS

Women experience ADRs nearly twice as often as men, yet the roles of gender and sex as biological and social factors that may increase the risk of ADRs are poorly understood (54). Trials do not always report efficacy stratified by gender or sex, and even less frequently for adverse events or safety outcomes (55). Across the globe, there is a combination of cultural and societal reasons why women and men approach health care differently and might be more or less likely to report adverse events to therapies (56).

An example is *CYP2D6* genotype-determined phenotypes and the observed difference in rates of ADRs for opioid users across sexes. According to a study undertaken using the Mayo Clinic Biobank, *CYP2D6* ultrarapid metabolizers are at a significantly greater risk of ADRs, including nausea, rash, and constipation, in response to opioid therapy (57). While there was no difference in drug efficacy (i.e., pain management) in the 2,877 opioid users examined, women were more likely than men to suffer from an ADR ($p = 0.002$). Among women, those who were ultrarapid or rapid metabolizers had a greater risk of ADRs compared to poor metabolizers, but this trend was not observed among men. There are hypothesized differences in *CYP2D6* activity between men and women, with pregnancy-induced changes in liver tissue uncovering potential mechanisms (58). However, it is apparent that more research into both the mechanism and extent of this effect is necessary. For example, do these effects observed in women abate after menopause, and are there observable differences in the extent of pain management?

Capturing information on effects of therapies, including ADRs, is challenging when using observational data resources. For example, in the long-term management of chronic pain using

opioids, women experience a 50–70% increased risk of ADRs compared to men (54). Certain adverse physical and mental health effects of long-term pain management, such as morphine-induced respiratory depression (57, 58), poor self-image, and increased nausea and vomiting, are observed more frequently in women (59, 60). At the same time, there are genes with known effects on opioid metabolism such as *COMT* and *OPRM1*. Indeed, sex modifies the effect of variants in these genes on known ADRs, where males and females with the risk genotypes in *OPRM1* and *COMT* experience different ADRs at significantly different rates (45).

Most drugs withdrawn from the market increased health risks for women (45, 61, 62), which is consistent with the poor representation of women in the trials that led to the approval and use of these drugs. Women represent only 38% of participants in drug efficacy and pharmacokinetic studies (46). Due to greater life expectancy in many regions of the world, women often comprise a higher proportion of the elderly population and are more likely to require polypharmacy and suffer the associated health risks and increased health-care burden. Therefore, the underrepresentation of women in clinical and research studies poses a grave challenge in developing appropriate clinical guidelines. Gender- and sex-stratified approaches would be the logical first step in applying precision medicine to pharmacogenomics, given the known impacts of sex and gender on the efficacy and safety of drugs, health-care interactions, and behaviors.

STEPS TOWARD ADDRESSING ANCESTRY AND SEX BIAS IN PHARMACOGENOMICS

Addressing ancestry and sex biases is crucial to ensuring that pharmacogenomic research is effective and equitable for all people. A concerted effort to include diverse populations is required. This includes people from different ancestral backgrounds as well as both men and women. Moreover, it is also important to avoid language that reinforces stereotypes or biases. For example, using terms such as Caucasian or Oriental can be outdated and offensive. Instead, the use of more neutral terms such as European or East Asian can help. Similarly, using inclusive language to describe gender is important.

In addition to genetics, social factors can also play a role in drug responses. For example, individuals with lower socioeconomic status may not be prescribed medications that are tailored to their genetics. Furthermore, some cultures may view genetic testing as invasive and unnecessary, which could lead to less willingness to participate in clinical trials involving pharmacogenomic testing. It is therefore crucial that these social factors be considered when designing studies (63). This can be achieved by engaging with communities to understand their experiences and concerns to build trust and ensure that research is relevant and impactful. Work with community groups is also necessary to identify research questions and study designs that are sensitive to cultural beliefs and practices.

Assuming that biases in data representation are addressed, widespread implementation of pharmacogenomics will still require numerous barriers to be overcome. The fact that many health-care providers are not familiar with pharmacogenomics and may not be aware of its potential benefits poses a significant barrier as well. For private and public health systems, the implementation of pharmacogenomics not only may be an expensive procedure to implement but also might lead to new inequalities for those patients with fewer resources who might not be able to afford it. Moreover, even if implementation is afforded, there is the challenge of standardization of testing. A myriad of procedures and technologies are available for implementation of pharmacogenomics in many labs. These labs may have different requirements and constraints in terms of which genotyping methods to apply. What to apply and what not remain in a state of flux, not least because of the evolving landscape of possible tests and results derived from them. All of this adds uncertainty in terms of how to comply with regulations related to pharmacogenomic

Table 3 Recommendations for addressing pharmacogenomics biases in ancestry and sex

Recommendation	What it means in practice
Increase awareness and education	Educate health-care providers on existence of ancestry and sex biases in pharmacogenomics Eliminate cultural biases (e.g., stereotypical language) Equalize study design biases (e.g., develop studies that include pregnant women)
Provide more equitable financial support	Avoid discrimination of less-resourced groups
Develop standards for pharmacogenomics implementation	Develop a minimum set of requirements for equality, diversity, and inclusion when testing patients Reduce technology biases (e.g., avoid genetic tests with overrepresentation of European-centric variants)
Address regulatory uncertainty	Reduce uncertainty in terms of how to best comply with regulation related to pharmacogenomic testing (e.g., what technologies to adopt, what quality controls should be necessary)
Augment evidence base	Include more diverse ancestral and sex data sets for more pharmacogenomically relevant drug targets
Facilitate integration into clinical workflows	Reduce barriers to clinical adoption by providing relevant infrastructure, resources, training, and support
Increase transparency	Share data and results openly with the public and obtain informed consent from participants

testing. Regulations for the implementation of testing may be further impaired by a lack of infrastructure, resources, or training to support the integration of pharmacogenomic testing into clinical care. For all of the above reasons, implementing ethical and transparent policies from the outset of research is fundamental (64). Policies may include sharing data and results openly with the public, obtaining informed consent from participants, and ensuring that study designs do not perpetuate biases or stigmatize particular groups.

In **Table 3**, we offer a set of recommendations for addressing pharmacogenomics biases in ancestry and sex.

CONCLUSION

Pharmacogenomics is a powerful tool for achieving precision medicine. Its applications have the power to help improve drug efficacy and avoid ADRs. Such tailor-made pharmacological strategies have the potential to provide personalized tools for titrating the right dose of the right drug to the right patient. We have shown that, to date, most of the data from which pharmacogenomics knowledge is derived are based on European and East Asian males. We observed that traditionally underrepresented biogeographical groups such as Africans, Latinos, and South/Central Asians continue to encompass a minimal fraction of existing pharmacogenomic data sets, in line with the already characterized GWAS data set biases. In this review, we have showcased the pharmacogenomics of *CYP2D6*, the gene that metabolizes the greatest proportion of prescribed drugs. Furthermore, women, who have historically been underrepresented in clinical trials, may present diseases differently than men, leading to gender bias in pharmacogenomics research. With the help of regulatory organizations, it is possible to establish and follow recommendations for how to prescribe different drugs. However, it is still required that recommendations embrace the intricacies of existing biases, which have relatively neglected sex- and ancestry-specific genetic differences, resulting in suboptimal pharmacological treatments for these groups. By addressing ancestry and sex bias in pharmacogenomics research, we can improve the accuracy and effectiveness of drug therapies and ensure that all patients receive the best possible care.

DISCLOSURE STATEMENT

At the time of writing, M.C. is associated with Cambridge Precision Medicine Ltd. D.G. is employed part time by Novo Nordisk, unrelated to the submitted work.

ACKNOWLEDGMENTS

S.F. is supported by the Wellcome Trust (220740/Z/20/Z) at the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit. R.M. is supported by Barts Charity (MGU0504). D.G. is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London.

LITERATURE CITED

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. 2001. Initial sequencing and analysis of the human genome. *Nature* 409(6822):860–921
2. Lauschke VM, Ingelman-Sundberg M. 2019. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. *Eur. J. Pharm. Sci.* 130:65–77
3. Malki MA, Pearson ER. 2020. Drug-drug-gene interactions and adverse drug reactions. *Pharmacogenom. J.* 20(3):355–66
4. Pirmohamed M. 2014. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. *Annu. Rev. Genom. Hum. Genet.* 15:349–70
5. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, et al. 2007. Association of warfarin dose with genes involved in its action and metabolism. *Hum. Genet.* 121(1):23–34
6. Zhang J, Wu T, Chen W, Fu J, Xia X, Chen L. 2019. Effect of gene-based warfarin dosing on anticoagulation control and clinical events in a real-world setting. *Front. Pharmacol.* 10:1527
7. Chan SL, Suo C, Lee SC, Goh BC, Chia KS, Teo YY. 2012. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. *Pharmacogenom. J.* 12(4):312–18
8. Agúndez JAG, Esguevillas G, Amo G, García-Martín E. 2014. Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs. *Front. Pharmacol.* 5:188
9. Huang RS, Ratain MJ. 2009. Pharmacogenetics and pharmacogenomics of anticancer agents. *CA Cancer J. Clin.* 59(1):42–55
10. Carr DF, Turner RM, Pirmohamed M. 2021. Pharmacogenomics of anticancer drugs: personalising the choice and dose to manage drug response. *Br. J. Clin. Pharmacol.* 87(2):237–55
11. Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. 2020. Women's participation in cardiovascular clinical trials from 2010 to 2017. *Circulation* 141(7):540–48
12. Yakerson A. 2019. Women in clinical trials: a review of policy development and health equity in the Canadian context. *Int. J. Equity Health* 18(1):56
13. Anaba U, Ishola A, Alabre A, Bui A, Prince M, et al. 2022. Diversity in modern heart failure trials: Where are we, and where are we going. *Int. J. Cardiol.* 348:95–101
14. Need AC, Goldstein DB. 2009. Next generation disparities in human genomics: concerns and remedies. *Trends Genet.* 25(11):489–94
15. Bustamante CD, De la Vega FM, Burchard EG. 2011. Genomics for the world. *Nature* 475(7355):163–65
16. Popejoy AB, Fullerton SM. 2016. Genomics is failing on diversity. *Nature* 538:161–64
17. Fatumo S, Chikowore T, Choudhury A, Ayub M, Martin AR, Kuchenbaecker K. 2022. A roadmap to increase diversity in genomic studies. *Nat. Med.* 28(2):243–50
18. Kamiza AB, Toure SM, Vujkovic M, Machipisa T, Soremekun OS, et al. 2022. Transferability of genetic risk scores in African populations. *Nat. Med.* 28(6):1163–66
19. Fatumo S, Inouye M. 2023. African genomes hold the key to accurate genetic risk prediction. *Nat. Hum. Behav.* 7:295–96
20. Fatumo S, Yakubu A, Oyedele O, Popoola J, Attipoe DA, et al. 2022. Promoting the genomic revolution in Africa through the Nigerian 100K Genome Project. *Nat. Genet.* 54(5):531–36

21. Hughes JH, Woo KH, Keizer RJ, Goswami S. 2022. Clinical decision support for precision dosing: opportunities for enhanced equity and inclusion in health care. *Clin. Pharmacol. Ther.* 113:565–74
22. Asiimwe IG, Zhang EJ, Osanlou R, Jorgensen AL, Pirmohamed M. 2021. Warfarin dosing algorithms: a systematic review. *Br. J. Clin. Pharmacol.* 87(4):1717–29
23. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, et al. 2021. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. *Clin. Pharmacol. Ther.* 110(3):563–72
24. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al. 2012. Pharmacogenomics knowledge for personalized medicine. *Clin. Pharmacol. Ther.* 92(4):414–17
25. Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, et al. 2019. Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. *Clin. Pharmacol. Ther.* 105(5):1256–62
26. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. 2020. A review of the important role of *CYP2D6* in pharmacogenomics. *Genes* 11(11):1295
27. Solovieff N, Hartley SW, Baldwin CT, Klings ES, Gladwin MT, et al. 2011. Ancestry of African Americans with sickle cell disease. *Blood Cells Mol. Dis.* 47(1):41–45
28. Ahmed S, Zhou Z, Zhou J, Chen S-Q. 2016. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. *Genom. Proteom. Bioinform.* 14(5):298–313
29. Del Tredici AL, Malhotra A, Dedek M, Espin F, Roach D, et al. 2018. Frequency of *CYP2D6* alleles including structural variants in the United States. *Front. Pharmacol.* 9:305
30. PharmGKB. 2023. *Gene-specific information tables for CYP2D6*. Inf. Tables, PharmGKB. <https://www.pharmgkb.org/page/cyp2d6RefMaterials>
31. Dean L, Kane M. 2021. Codeine therapy and *CYP2D6* genotype. In *Medical Genetics Summaries*, ed. VM Pratt, SA Scott, M Pirmohamed. Bethesda, MD: Natl. Cent. Biotechnol. Inf.
32. Deleted in proof
33. Twesigomwe D, Drögemöller BI, Wright GEB, Adebamowo C, Agongo G, et al. 2023. Characterization of *CYP2D6* pharmacogenetic variation in sub-Saharan African populations. *Clin. Pharmacol. Ther.* 113(3):643–59
34. Rajman I, Knapp L, Morgan T, Masimirembwa C. 2017. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. *EBioMedicine* 17:67–74
35. Ortega VE, Meyers DA. 2014. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. *J. Allergy Clin. Immunol.* 133(1):16–26
36. Magavern EF, Gurdasani D, Ng FL, Lee SS-J. 2022. Health equality, race and pharmacogenomics. *Br. J. Clin. Pharmacol.* 88(1):27–33
37. Goodman CW, Brett AS. 2021. Race and pharmacogenomics—personalized medicine or misguided practice? *JAMA* 325(7):625–26
38. Viera de Lara D, Oliveira de Melo D, Araujo Silva LC, Gonçalves TS, Lima Santos PCJ. 2022. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews. *Pharmacogenomics* 23(7):443–52
39. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. 2010. Combined *CYP2C9*, *VKORC1* and *CYP4F2* frequencies among racial and ethnic groups. *Pharmacogenomics* 11(6):781–91
40. Ndadza A, Muyambo S, Mntla P, Wonkam A, Chimusa E, et al. 2021. Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. *J. Thromb. Haemost.* 19(12):2957–73
41. Dean L. 2012. Warfarin therapy and *VKORC1* and *CYP* genotypes. In *Medical Genetics Summaries*, ed. VM Pratt, SA Scott, M Pirmohamed. Bethesda, MD: Natl. Cent. Biotechnol. Inf.
42. Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. 2017. Warfarin pharmacogenomics in diverse populations. *Pharmacother. J. Hum. Pharmacol. Drug Ther.* 37(9):1150–63
43. Asiimwe IG, Pirmohamed M. 2022. Ethnic diversity and warfarin pharmacogenomics. *Front. Pharmacol.* 13:866058
44. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, et al. 2021. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. *Eur. J. Prev. Cardiol.* 28(8):805–12

45. Planelles B, Margarit C, Inda M-D-M, Ballester P, Muriel J, et al. 2020. Gender based differences, pharmacogenetics and adverse events in chronic pain management. *Pharmacogenom. J.* 20(2):320–28
46. Knadler MP, Lobo E, Chappell J, Bergstrom R. 2011. Duloxetine: clinical pharmacokinetics and drug interactions. *Clin. Pharmacokinet.* 50(5):281–94
47. Dawed AY, Mari A, Brown A, McDonald TJ, Li L, et al. 2023. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. *Lancet Diabetes Endocrinol.* 11(1):33–41
48. Pinho-Gomes A-C, Carcel C, Woodward M, Hockham C. 2023. Women's representation in clinical trials of patients with chronic kidney disease. *Clin. Kidney J.* 16(9):1457–64
49. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. *J. Clin. Endocrinol. Metab.* 94(7):2537–43
50. Cui Q, Ju X, Yang T, Zhang M, Tang W, et al. 2010. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. *Atherosclerosis* 213(2):632–36
51. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, et al. 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N. Engl. J. Med.* 376(18):1713–22
52. Cordero A, Fernández Del Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, et al. 2022. Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry. *J. Cardiovasc. Pharmacol.* 79(4):523–29
53. Myasoedova VA, Rimbert A, Camera M, Le May C, Capoulade R, et al. 2023. LDL lowering effect of PCSK9 inhibition is reduced in women. *Eur. Heart J. Cardiovasc. Pharmacother.* 9(4):337–42
54. Zucker I, Prendergast BJ. 2020. Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biol. Sex Differ.* 11(1):32
55. Pilote L, Raparelli V. 2018. Participation of women in clinical trials: not yet time to rest on our laurels. *J. Am. Coll. Cardiol.* 71(18):1970–72
56. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero J-J, et al. 2020. Sex and gender: modifiers of health, disease, and medicine. *Lancet* 396(10250):565–82
57. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, et al. 2000. Sex differences in morphine analgesia: an experimental study in healthy volunteers. *Anesthbesiology* 93(5):1245–54
58. Dahan A, Sarton E, Teppema L, Olivier C. 1998. Sex-related differences in the influence of morphine on ventilatory control in humans. *Anesthbesiology* 88(4):903–13
59. Zun LS, Downey LVA, Gossman W, Rosenbaumdagger J, Sussman G. 2002. Gender differences in narcotic-induced emesis in the ED. *Am. J. Emerg. Med.* 20(3):151–54
60. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. 2003. Side effects of opioids during short-term administration: effect of age, gender, and race. *Clin. Pharmacol. Ther.* 74(2):102–12
61. Anthony M, Berg MJ. 2002. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: part I. *J. Women's Health Gen.-Based Med.* 11(7):601–15
62. Anthony M, Berg MJ. 2002. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. *J. Women's Health Gen.-Based Med.* 11(7):617–29
63. Bansal S, Mahendiratta S, Prakash A, Medhi B. 2021. Social pharmacology and its impact on clinics. *Indian J. Pharmacol.* 53(6):437–39
64. Zarin DA, Tse T. 2008. Moving toward transparency of clinical trials. *Science* 319(5868):1340–42



Contents

Gene-Environment Interactions: My Unique Journey <i>Daniel W. Nebert</i>	1
Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment” <i>Urs A. Meyer, Susan G. Amara, Terrence F. Blaschke, and Paul A. Insel</i>	27
Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward <i>Völker M. Lauschke, Yitian Zhou, and Magnus Ingelman-Sundberg</i>	33
Addressing Ancestry and Sex Bias in Pharmacogenomics <i>Manuel Corpas, Moneeza K. Siddiqui, Opeyemi Soremekun, Robini Mathur, Dipender Gill, and Segun Fatumo</i>	53
Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes <i>Roman Tremmel, Ute Hofmann, Mathias Haag, Elke Schaeffeler, and Matthias Schwab</i>	65
Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy <i>Francis A. Lévi, Alper Okyar, Eva Hadadi, Pasquale F. Innominato, and Annabelle Ballesta</i>	89
Anthracycline Toxicity: Light at the End of the Tunnel? <i>Romina B. Cejas, Kateryna Petrykey, Yadav Sapkota, and Paul W. Burridge</i>	115
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics <i>Erfan Tasdighi, Rishav Adbikari, Omar Almaadawy, Thorsten M. Leucker, and Michael J. Blaha</i>	135
Health Digital Twins in Life Science and Health Care Innovation <i>Kaushik P. Venkatesh, Gabriel Brito, and Maged N. Kamel Boulos</i>	159

The Nocebo Effect <i>Luana Colloca</i>	171
High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions <i>Caitlin Lynch, Srilatha Sakamuru, Masato Ooka, Ruili Huang, Carleen Klumpp-Thomas, Paul Shinn, David Gerhold, Anna Rossosbek, Sam Michael, Warren Casey, Michael F. Santillo, Suzanne Fitzpatrick, Russell S. Thomas, Anton Simeonov, and Menghang Xia</i>	191
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss <i>John Lee, Katharine Fernandez, and Lisa L. Cunningham</i>	211
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance <i>Ruth Nussinov and Hyunbum Jang</i>	231
Alcohol Use Disorder Treatment: Problems and Solutions <i>George F. Koob</i>	255
Targeting the Actions of Muscarinic Receptors on Dopamine Systems: New Strategies for Treating Neuropsychiatric Disorders <i>Eric J. Nunes, Nii A. Addy, P. Jeffrey Conn, and Daniel J. Foster</i>	277
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation <i>Vladas Oleinikovas, Pablo Gainza, Thomas Ryckmans, Bernhard Fasching, and Nicolas H. Thomä</i>	291
Apathy and Motivation: Biological Basis and Drug Treatment <i>Harry Costello, Masud Husain, and Jonathan P. Roiser</i>	313
Targeting Efferocytosis in Inflammaging <i>Ivan K.H. Poon and Kodi S. Ravichandran</i>	339
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease <i>Jarrah O.-Z.J. Kron, Ryan J. Keenan, Daniel Hoyer, and Laura H. Jacobson</i>	359
G Protein–Coupled Receptor Signaling: New Insights Define Cellular Nanodomains <i>Martin J. Lobse, Andreas Bock, and Manuela Zaccolo</i>	387
Molecular Activation of NLRP3 Inflammasome by Particles and Crystals: A Continuing Challenge of Immunology and Toxicology <i>Qiang Ma and Chol Seung Lim</i>	417
Translational In Vivo Assays in Behavioral Biology <i>Sarah L. Witbey, Diego A. Pizzagalli, and Jack Bergman</i>	435

Mass Spectrometry–Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine <i>Sunil K. Joshi, Paul Piehowski, Tao Liu, Sara J.C. Gosline, Jason E. McDermott, Brian J. Druker, Elie Traer, Jeffrey W. Tyner, Anupriya Agarwal, Cristina E. Tognon, and Karin D. Rodland</i>	455
Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases <i>Ekaterini Tiligada, Daria Gafarov, Maria Zaimi, Joana Vitte, and Francesca Levi-Schaffer</i>	481
Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution <i>Zhengyuan Pang, Benjamin F. Cravatt, and Li Ye</i>	507
Artificial Intelligence for Drug Discovery: Are We There Yet? <i>Catrin Hasselgren and Tudor I. Oprea</i>	527
Oral Anticoagulants Beyond Warfarin <i>Renske H. Olie, Kristien Winckers, Bianca Rocca, and Hugo ten Cate</i>	551
Antiepileptic Drugs as Potential Dementia Prophylactics Following Traumatic Brain Injury <i>Laszlo F. Locskai, Hadeel Alyenbaawi, and W. Ted Allison</i>	577

Indexes

Cumulative Index of Contributing Authors, Volumes 60–64	599
Cumulative Index of Article Titles, Volumes 60–64	604

Errata

An online log of corrections to *Annual Review of Pharmacology and Toxicology* articles may be found at <http://www.annualreviews.org/errata/pharmtox>

Related Articles

From the *Annual Review of Biochemistry*, Volume 92 (2023)

The Proteins of mRNA Modification: Writers, Readers, and Erasers

Mathieu N. Flamand, Matthew Tegowski, and Kate D. Meyer

The Activation Mechanism of the Insulin Receptor: A Structural Perspective

Eunbee Choi and Xiao-Chen Bai

The Inseparable Relationship Between Cholesterol and Hedgehog Signaling

Christian Siebold and Rajat Robatgi

Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection

Stephanie Vrijzen, Marine Houdou, Ana Cascalho, Jan Eggermont, and Peter Vangheluwe

From the *Annual Review of Cancer Biology*, Volume 7 (2023)

Reinventing Radiobiology in the Light of FLASH Radiotherapy

Charles L. Limoli and Marie-Catherine Vozenin

Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies

Diego Salas-Benito, Trisha R. Berger, and Marcela V. Maus

New Tools for Lineage Tracing in Cancer In Vivo

Matthew G. Jones, Dian Yang, and Jonathan S. Weissman

Strategies for Heating Up Cold Tumors to Boost Immunotherapies

Daniel J. Zabransky, Mark Yarchoan, and Elizabeth M. Jaffee

The Potent and Paradoxical Biology of Cellular Senescence in Cancer

Paul B. Romesser and Scott W. Lowe

CAR NK Cells: The Future Is Now

Martin J. Raftery, Alexander Sebastian Franzén, and Gabriele Pecher

Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy

Emmett V. Schmidt, Linda Z. Sun, Adam C. Palmer, and Cong Chen

The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics

Joelle P. Straehla, David A. Reardon, Patrick Y. Wen, and Nathalie Y.R. Agar

On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer

Matthew D. Park, Meriem Belabed, Steven T. Chen, Pauline Hamon, Samarth Hegde, Raphaël Mattiuz, Thomas U. Marron, and Miriam Merad

Next-Generation Estrogen Receptor–Targeted Therapeutics
Tharu M. Fernando, Heather M. Moore, Matthew J. Wongchenko, and Ciara Metcalfe

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell
Receptor–Based Cellular Therapy
Tijana Martinov and Philip D. Greenberg

From the *Annual Review of Genetics*, Volume 57 (2023)

Interplay Between Antimicrobial Resistance and Global Environmental Change
María Mercedes Zambrano

From the *Annual Review of Immunology*, Volume 41 (2023)

Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Oleksandr Kyrysyuk and Kai W. Wucherpfennig

Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation
Jianing Fu and Hao Wu

T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, and Shane Crotty

Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond
Simone Caielli, Zurong Wan, and Virginia Pascual

Interfering with Interferons: A Critical Mechanism for Critical
COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, and Jean-Laurent Casanova

From the *Annual Review of Medicine*, Volume 74 (2023)

COVID-19 Thrombotic Complications and Therapeutic Strategies
Alexander C. Fanaroff and Renato D. Lopes

SARS-CoV-2 Vaccination-Induced Thrombotic Thrombocytopenia:
A Rare but Serious Immunologic Complication
Charles S. Abrams and Geoffrey D. Barnes

Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment
in Transplant Recipients
Jennifer L. Saullo and Rachel A. Miller

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated
Hormone-Based Therapeutics
Ania M. Jastreboff and Robert F. Kushner

Valvular Heart Disease: New Concepts in Pathophysiology
and Therapeutic Approaches
Mackram F. Eleid, Vuyisile T. Nkomo, Sorin V. Pislaru, and Bernard J. Gersh

Lessons Learned from the ISCHEMIA Trial for the Management of Patients with Stable Ischemic Heart Disease

William E. Boden and Peter H. Stone

Maternal Mortality in the United States: Trends and Opportunities for Prevention

Siwen Wang, Kathryn M. Rexrode, Andrea A. Florio, Janet W. Rich-Edwards, and Jorge E. Chavarro

Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys

Jordana B. Cohen, Irina Bancos, Jenifer M. Brown, Harini Sarathy, Adina F. Turcu, and Debbie L. Cohen

Adeno-Associated Virus Gene Therapy for Hemophilia

Benjamin J. Samelson-Jones and Lindsey A. George

Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss

Fateeha Furqan and Nirav N. Shah

Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacologic Perturbations

Gregg L. Semenza

Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches

Stephanie Lazar and J. Michelle Kablenberg

SGLT2 Inhibitors: The Sweet Success for Kidneys

Atit Dharra, Abid Khan, Vikas S. Sridhar, and David Z.I. Cherney

Cystic Fibrosis Modulator Therapies

Shijing Jia and Jennifer L. Taylor-Cousar

Club Cell Secretory Protein in Lung Disease: Emerging Concepts and Potential Therapeutics

Tereza Martinu, Jamie L. Todd, Andrew E. Gelman, Stefano Guerra, and Scott M. Palmer

Diverse Approaches to Gene Therapy of Sickle Cell Disease

Shanna L. White, Kevyn Hart, and Donald B. Kohn

From the *Annual Review of Neuroscience*, Volume 46 (2023)

Therapeutic Potential of PTBP1 Inhibition, If Any, Is Not Attributed to Glia-to-Neuron Conversion

Lei-Lei Wang and Chun-Li Zhang

Therapeutic Potential of PTB Inhibition Through Converting Glial Cells to Neurons in the Brain

Xiang-Dong Fu and William C. Mobley

Deep Brain Stimulation for Obsessive-Compulsive Disorder and Depression

Sameer A. Sheth and Helen S. Mayberg

From the *Annual Review of Pathology: Mechanisms of Disease*, Volume 18 (2023)

Tumor Microenvironment in Pancreatic Cancer Pathogenesis
and Therapeutic Resistance

Mara H. Sherman and Gregory L. Beatty

Tumor-Derived Extracellular Vesicles: Multifunctional Entities
in the Tumor Microenvironment

James W. Clancy and Crislyn D'Souza-Schorey

New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in
Diagnosis and Therapy

*Peter Valent, Cem Akin, Wolfgang R. Sperr, Hans-Peter Horny, Michel Arock,
Dean D. Metcalfe, and Stephen J. Galli*

The Pathology of Asthma: What Is Obstructing Our View?

Helena Aegerter and Bart N. Lambrecht

From the *Annual Review of Physiology*, Volume 85 (2023)

Molecular Physiology of TRPV Channels: Controversies and Future Challenges

Tamara Rosenbaum and León D. Islas

Insulin Clearance in Health and Disease

Sonia M. Najjar, Sonia Caprio, and Amalia Gastaldelli

From the *Annual Review of Statistics and Its Application*, Volume 10 (2023)

Surrogate Endpoints in Clinical Trials

Michael R. Elliott

Statistical Data Privacy: A Song of Privacy and Utility

Aleksandra Slavković and Jeremy Seeman